![Camilla Sylvest](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Camilla Sylvest
Directeur/Membre du Conseil chez
ARGENX SE
Fortune : 3 M $ au 30/06/2026
Profil
Camilla Sylvest is currently an Independent Non-Executive Director at argenx SE since 2022, a Director at Zealand Pharma A starting in 2026, and an Independent Director at Getinge AB starting in 2026.
Former roles include Vice Chairman at World Diabetes Foundation, Independent Director at Danish Crown A, Senior Vice President & General Manager-Germany at Novo Nordisk Pharma GmbH, and EVP-Commercial Strategy & Corporate Affairs at Novo Nordisk A from 2017 to 2025.
Education includes a graduate degree from the University of Southern Denmark in 1998 and an MBA from Scandinavian International Management Institute in 2003.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ARGENX SE 0 % | 30/06/2026 | 3 049 ( 0 % ) | 3 M $ | 30/06/2026 |
Postes actifs de Camilla Sylvest
| Sociétés | Poste | Début |
|---|---|---|
| ARGENX SE | Directeur/Membre du Conseil | 08/09/2022 |
| GETINGE AB | Directeur/Membre du Conseil | 21/04/2026 |
| ZEALAND PHARMA A/S | Directeur/Membre du Conseil | 26/05/2026 |
Anciens postes connus de Camilla Sylvest
| Sociétés | Poste | Fin |
|---|---|---|
| NOVO NORDISK A/S | Corporate Officer/Principal | 03/04/2025 |
World Diabetes Foundation
 World Diabetes Foundation Investment Trusts/Mutual FundsMiscellaneous Functions as a foundation or endowment | Directeur/Membre du Conseil | - |
Danish Crown A/S
 Danish Crown A/S Food: Meat/Fish/DairyConsumer Non-Durables Engages in processing and sale of chilled & frozen meat products, pork, beef, poultry and lamb | Directeur/Membre du Conseil | - |
Novo Nordisk Pharma GmbH
 Novo Nordisk Pharma GmbH Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products | Corporate Officer/Principal | - |
Formation de Camilla Sylvest
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
56
Relations au 1er degré
9
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 9 |
|---|---|
Novo Nordisk A/S
 Novo Nordisk A/S Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products for diabetes care | Health Technology |
Novo Nordisk Pharma GmbH
Novo Nordisk Pharma GmbH Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products | Health Technology |
Getinge AB
 Getinge AB Medical SpecialtiesHealth Technology Manufactures and distributes medical devices and disinfectants | Health Technology |
Zealand Pharma A/S
 Zealand Pharma A/S BiotechnologyHealth Technology Operates as a biotechnology company that discovers and develops peptide based medicines | Health Technology |
University of Southern Denmark
 University of Southern Denmark Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Scandinavian International Management Institute
 Scandinavian International Management Institute Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Danish Crown A/S
Danish Crown A/S Food: Meat/Fish/DairyConsumer Non-Durables Engages in processing and sale of chilled & frozen meat products, pork, beef, poultry and lamb | Consumer Non-Durables |
argenx SE
 argenx SE BiotechnologyHealth Technology Develops therapies and medicines for the treatment of autoimmune diseases | Health Technology |
World Diabetes Foundation
World Diabetes Foundation Investment Trusts/Mutual FundsMiscellaneous Functions as a foundation or endowment | Miscellaneous |
Choisissez Zonebourse 
